普洛药业
(000739)
| 流通市值：179.89亿 | | | 总市值：179.96亿 |
| 流通股本：11.69亿 | | | 总股本：11.69亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,021,863,029.21 | 9,290,220,207.76 | 6,428,714,752.29 | 3,198,046,619.86 |
| 营业收入 | 12,021,863,029.21 | 9,290,220,207.76 | 6,428,714,752.29 | 3,198,046,619.86 |
| 二、营业总成本 | 10,858,989,886.75 | 8,295,069,270.45 | 5,651,769,473.26 | 2,862,663,780.78 |
| 营业成本 | 9,155,202,967.93 | 7,039,196,715.18 | 4,840,895,523.11 | 2,429,103,622.29 |
| 税金及附加 | 56,309,811.43 | 38,464,108.76 | 27,691,554.27 | 8,361,997.65 |
| 销售费用 | 640,232,098.94 | 399,845,866 | 280,576,659.93 | 152,627,121.84 |
| 管理费用 | 480,940,845.39 | 364,405,634.04 | 234,373,187.88 | 123,254,329.94 |
| 研发费用 | 641,471,760.73 | 467,201,967.23 | 314,769,509.42 | 152,938,500.76 |
| 财务费用 | -115,167,597.67 | -14,045,020.76 | -46,536,961.35 | -3,621,791.7 |
| 其中:利息费用 | 28,581,876.49 | 22,658,655.71 | 15,432,755.6 | 8,422,207.91 |
| 其中:利息收入 | 92,174,157.39 | 61,734,298.32 | 38,720,756.24 | 10,977,859.8 |
| 加:公允价值变动收益 | 7,965,391.23 | 8,469,505.02 | -2,535,659.78 | -2,832,381.83 |
| 加:投资收益 | -18,092,847.19 | -8,133,805.36 | -723,423.58 | -2,018,356.21 |
| 资产处置收益 | 279,470.84 | 940,320.95 | 567,328.49 | 278,035.93 |
| 资产减值损失(新) | -70,224,534.92 | -64,057,956.27 | -69,037,026.68 | -30,041,951.83 |
| 信用减值损失(新) | 921,524.36 | 4,482,243.72 | -23,456,851.24 | -23,590,931.18 |
| 其他收益 | 128,348,756.48 | 86,271,219.6 | 58,683,210.82 | 23,121,109.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,212,070,903.26 | 1,023,122,464.97 | 740,442,857.06 | 300,298,363.68 |
| 加:营业外收入 | 1,643,305.98 | 1,534,043.08 | 910,434.62 | 480,645.43 |
| 减:营业外支出 | 10,423,836.23 | 4,812,177.38 | 2,849,204.9 | 1,289,063 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,203,290,373.01 | 1,019,844,330.67 | 738,504,086.78 | 299,489,946.11 |
| 减:所得税费用 | 172,443,650.71 | 150,456,206.83 | 113,858,949.43 | 55,775,945.03 |
| 六、净利润 | 1,030,846,722.3 | 869,388,123.84 | 624,645,137.35 | 243,714,001.08 |
| 持续经营净利润 | 1,030,846,722.3 | 869,388,123.84 | 624,645,137.35 | 243,714,001.08 |
| 归属于母公司股东的净利润 | 1,031,121,698.55 | 869,652,417.71 | 624,842,853.55 | 243,716,289.99 |
| 少数股东损益 | -274,976.25 | -264,293.87 | -197,716.2 | -2,288.91 |
| (一)基本每股收益 | 0.89 | 0.75 | 0.54 | 0.21 |
| (二)稀释每股收益 | 0.89 | 0.75 | 0.54 | 0.21 |
| 八、其他综合收益 | 10,713,506.8 | 3,571,372.34 | 874,296.24 | 743,150.25 |
| 归属于母公司股东的其他综合收益 | 10,713,506.8 | 3,571,372.34 | 874,296.24 | 743,150.25 |
| 九、综合收益总额 | 1,041,560,229.1 | 872,959,496.18 | 625,519,433.59 | 244,457,151.33 |
| 归属于母公司股东的综合收益总额 | 1,041,835,205.35 | 873,223,790.05 | 625,717,149.79 | 244,459,440.24 |
| 归属于少数股东的综合收益总额 | -274,976.25 | -264,293.87 | -197,716.2 | -2,288.91 |
| 公告日期 | 2025-03-11 | 2024-10-18 | 2024-08-16 | 2024-04-18 |
| 审计意见(境内) | 标准无保留意见 | | | |